About Us
Our Company was established.
Acquired the PCFiT™ technology platform and obtained global rights to all its pipelines; Completed Series A Financing.
Acquired the Apitope® technology platform and obtained global rights to all its pipelines.
Completed Series B Financing
Established a laboratory in Shanghai; Completed the acquisition of Diater in Spain;Completed Series C Financing.
Completed Series D Financing.
Initiated a Phase I clinical trial of WP1302.
A wholly-owned subsidiary of Worg PHARMA
